



## **Akerro Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference**

October 17, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akerro Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present virtually at the H.C. Wainwright 7<sup>th</sup> Annual NASH Conference on Tuesday, October 24, 2023, at 12:00 p.m. E.T.

A live webcast of the fireside chat will be available through the investor relations section of the Company's website at [www.akerotx.com](http://www.akerotx.com). Following the live webcast, an archived replay will be available on the Company's website.

### **About Akerro Therapeutics**

Akerro Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH, a disease without any approved therapies. Akerro's lead product candidate, EFX, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Akerro is headquartered in South San Francisco. Visit us at [akerotx.com](http://akerotx.com) and follow us on [LinkedIn](#) and [Twitter](#) for more information.

### **Investor Contact:**

Austin Murtagh  
212.698.8696  
[IR@akerotx.com](mailto:IR@akerotx.com)

### **Media Contact:**

Sarah O'Connell  
732.456.0092  
[soconnell@vergescientific.com](mailto:soconnell@vergescientific.com)